Sana Biotechnology

Sana Biotechnology to webcast panel at Goldman Sachs Cell Therapy Day Conference on Oct 1, 2024, featuring CEO Steve Harr. Webcast available on Sana's Investor Relations page, with replay for 30 days.

Richard Mulligan, Director at Sana Biotechnology, sold 300,000 shares for $1,195,740 on Sept 24-25, 2024, under a Rule 10b5-1 plan. He now directly owns 2,698,121 shares.

Sana Biotechnology, Inc. (SEC File No. 001-39941) plans to sell 150,000 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $613,500.00. The shares were acquired via restricted stock awards on 12/01/2019. Director Richard Mulligan, for whose account the securities are to be sold, represents no undisclosed material adverse information. No sales reported in the past 3 months.

Sana Biotechnology's stock price dropped 4.1% to $4.43 during mid-day trading, with a significant decline in trading volume. Brokerages like HC Wainwright, Rodman & Renshaw, and Citigroup maintain 'buy' ratings with varying price targets. The company reported a quarterly EPS of -$0.32, missing estimates by -$0.04. Institutional investors, including Swiss National Bank and PFM Health Sciences LP, increased their stakes in the company.

Sana Biotechnology's stock surged 9.6% to $4.70, with analysts setting new price targets: HC Wainwright at $11.00, Rodman & Renshaw at $16.00, and Citigroup at $15.00. Institutional investors increased holdings, with PFM Health Sciences LP raising its stake by 51.4%.

Nathan Hardy notified Sana Biotechnology on September 6 of his intention to resign as Executive Vice President and Chief Financial Officer, effective October 4, for personal reasons without disagreement on company matters.

Sana Biotechnology (NASDAQ:SANA) fell 3.4% to $4.82, trading at $4.81, with 175,844 shares traded, a 92% decline from average volume. Analysts issued 'buy' ratings with price targets ranging from $11.00 to $16.00. The company reported a $0.32 EPS miss, with anticipated -$1.13 EPS for the fiscal year. Institutional investors increased stakes, owning 88.23% of the stock.